Back to search
Indolent or Intermediate Grade B-cell Malignancy
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Indolent or Intermediate Grade B-cell Malignancy trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Indolent or Intermediate Grade B-cell Malignancy trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This phase II trial studies how well nivolumab works with the DA-REPOCH chemotherapy regimen in treating patients with aggressive B-cell non-Hodgkin lymphoma. I…
The purpose of this study is to assess the feasibility of a 60 minute rapid infusion rituximab protocol in the institution's outpatient infusion center.
This research study will only include two types of non-Hodgkin Lymphoma (NHL), follicular lymphoma or marginal zone lymphoma and participants will be age 70 or…
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining interferon alfa or the monocl…